Study S001835

A Phase 1, Open-Label, Multiple-Dose Study to Investigate the Comparability of the Pharmacokinetics of Orforglipron (LY3502970) Single Capsule and Multiple Capsules in Healthy Participants

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06692348
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 86
Start: 2024-12-13
Primary completion: 2025-06-09
Lead sponsor: Eli Lilly and Company
Conditions: Healthy
Interventions: DRUG:Orforglipron
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: OTHER:J2A-JE-GZPM

Registered primary outcomes

Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State) [Week 3 Through Week 16]
PK: Steady-state Maximum Concentration (Cmax) of Orforglipron (Fasted State) [Week 3 Through Week 16]
PK: Steady-state AUC of Orforglipron (Fed State) [Week 3 Through Week 16]
PK: Steady-state Cmax of Orforglipron (Fed State) [Week 3 Through Week 16]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.